Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa
Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).
Related posts:
- Lastest Xenical News
- Latest Celebrex News
- Latest “xenical” News
- Latest Generic Drugs News
- Latest Levitra News